Research partnership with industry? Apply today!

Dr Marek Tyl Written by Dr Marek Tyl
Published on 10 February 2017
2 min. read
We invite you to submit research proposals to the SHIONOGI Science Program, an international collaboration call for drug discovery. The collaboration research budget will be a maximum of JPY 15 million per year per project for up to three years.
 
Shionogi has a strong track record in productivity in drug discovery. They generate more than 60% of the development products in their pipeline. The products they are developing include candidate drugs originating from the Shionogi Research Laboratories, those from external seeds, and products derived from collaborative research with academic scientists and biopharmaceutical companies. Their strength is that they do not rely solely on in-house development, and develop drugs that incorporate a wide variety of ideas.
 
The SHIONOGI Science Program will be open for scientists who are based in Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, New Zealand, the Netherlands, and the UK. The application areas for this year are infectious diseases, CNS and pain research.
 
You can find details of the research themes and the submission guidelines at SHIONOGI INNOVATION. The proposals should be submitted electronically via the Application Form.
 
[Key Dates]
 
Proposal submissions for primary selection:
 
Primary selection results sent by:
 
Proposal submissions for secondary (final) selection:
 
Final decision notified by:
 
For general information on Shionogi Open Innovation, please visit SHIONOGI INNOVATION.
 
For any questions specific to the SHIONOGI Science Program, please contact SHIONOGI Science Program Team at [email protected].
Share content

Leave a Reply

In order to comment you need to be part of Inno-Forum. If you’re already a member Log in or Register

We use cookies to ensure that we give you the best tailored experience on our website based on your preferences. By continuing to use our services, you are giving us your consent to use cookies. Learn more here.